Best Genomics Companies in Bavaria, Germany
The 44 best Genomics companies in Bavaria, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ATAI.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Bavaria
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATAI 🦄 Biopharmaceutical company accelerating the development of mental health treatments | $387M | 65 mo ago | Public | Lars Christian Wilde Co-Founder | 119 | — | — | — |
| 2 | Isarna Therapeutics Developer of TGF-B inhibitors based therapies for ophthalmic, fibrotic diseases and cancer | $158M | 148 mo ago | Series F | — | 3 | — | 64 patents Patents concentrated in chemistry & materials | — |
| 3 | Ingenium Pharamceutical Discovering drug targets through Deductive Genomics | $71M | 244 mo ago | Acquired | John Watkins President & CEO | 41 | — | — | — |
| 4 | GPC Biotech Developing oncology therapies | $44M | 230 mo ago | Public | Elmar Maier Co-Founder | — | — | 126 patents Patents concentrated in health & consumer products | — |
| 5 | Ethris Developer of mRNA therapeutics for infectious diseases 55Patents top 25%Talent top 28%Moat top 29%Product top 30% All 11 signals ▾Patentstop 25% Talenttop 28% Moattop 29% Producttop 30% Innovationtop 35% Fundingtop 36% Growthtop 48% Techbottom 48% Marketbottom 44% Globalbottom 42% Newsbottom 27% Patents: 387 patents matched (strict assignee match) · 116 filings since 2022 vs 192 in 2017-21 Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 15 mo ago | Series B | — | 49 49 → 34 (-31%) | Top 10M | 387 patents mRNA therapeutic design, purification, and formulation with deuterated nucleotides | — |
| 6 | ISAR Bioscience Developer of regenerative medicine | $23M | 33 mo ago | Funding Raised | — | 19 | Top 10M | 15 patents Patents concentrated in chemistry & materials | — |
| 7 | GNA Biosolutions Develops instruments, OEM modules and assays for molecular pathogen detection | $20M | 84 mo ago | Series C | — | 29 | — | 96 patents Patents concentrated in chemistry & materials | — |
| 8 | mbiomics Provider of a genomic-based platform for microbiome-based therapeutics development 21Funding top 39%Patents top 39%Moat top 42%Innovation top 50% All 6 signals ▾Fundingtop 39% Patentstop 39% Moattop 42% Innovationtop 50% Globalbottom 36% Marketbottom 26% Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 3 mo ago | Series A | — | 7 | — | 13 patents RNA purification methods and microbiome analysis/composition technologies for diagnostic applications | — |
| 9 | FRIZ Biochem DNA-chip based biosensor for SNP detection | $3M | 140 mo ago | Public | Gerhard Hartwich CEO | — | — | 63 patents Microfluidic and functionalized assay platforms for biomolecule detection and surface conjugation | — |
| 10 | SYNLAB Provider of medical diagnosis and clinical laboratory analysis services | $2M | 115 mo ago | Public | Mathieu Floreani CEO | 28,693 | Top 1M | 5 patents Kidney disease progression diagnostics using homoarginine as a biomarker | — |
| 11 | Baseclick Holders of rights to new procedures in click chemistry and DNA photography. | $1M | 46 mo ago | Series B | — | 14 14 → 10 (-29%) | Top 10M | 118 patents Click‑chemistry‑enhanced mRNA synthesis, modification, and library amplification for vaccine therapeutics | — |
| 12 | Molecular Networks Cheminformatics software for drug discovery | $1M | 63 mo ago | Funding Raised | Johann Gasteiger Founder | — | Top 50M | — | — |
| 13 | Axolabs Preclinical to commercial scale research services for developing oligonucleotide therapeutics | $947K | 69 mo ago | Funding Raised | — | 118 118 → 215 (+82%) | Top 5M | 30 patents Sensitive detection kits for therapeutic oligonucleotide conjugates in molecular diagnostics | — |
| 14 | Ibidi Products and reagents for cell-based assay and microscopy | $817K | 79 mo ago | Funding Raised | Valentin Kahl CEO | — | Top 1M | 147 patents Patents concentrated in transport & manufacturing processes | 1 launch · 1 partnership |
| 15 | Leopard Provider of genomic-based test kits for diisease diagnostics | $545K | 35 mo ago | Seed | Mikkel Noerholm Co-Founder & CEO | — | — | — | — |
| 16 | Sirion Biotech Provides customised AAV based viral vectors and gene therapy | $494K | 127 mo ago | Acquired | — | 42 | — | 79 patents Engineering viral vectors and vaccine platforms for gene therapy and therapeutic vaccines | — |
| 17 | AptaIT Provider of a software tool for data analysis of next-generation sequencing data | $367K | 139 mo ago | Deadpooled | Michael Blank Co-Founder & CSO | — | — | — | — |
| 18 | Loewe Biochemica Develops plant disease detection tools | $291K | 99 mo ago | Funding Raised | Renate Loewe Founder & CEO | — | Top 50M | — | — |
| 19 | BioVariance Crowd-sourced platform for capture and analysis of drug dosage, adherence and adverse events | $260K | 79 mo ago | Funding Raised | Josef Scheiber Founder & MD | 18 | Top 50M | 2 patents Syringe‑adapted medicament delivery devices for precise drug administration. | — |
| 20 | Vermicon Developer of a gene probe technology to diagnose microorganisms | $245K | 118 mo ago | Funding Raised | Jiri Snaidr Founder & CEO | 9 | Top 10M | 32 patents Rapid, specific detection of microorganisms, especially gram‑positive bacteria, via biosensor assays | — |
Top 12 Genomics companies in Bavaria
#1
Series A · Munich, Bavaria · founded 2020 · 7 employees$14Mraised▾
Provider of a genomic-based platform for microbiome-based therapeutics development. It offers platforms that combine DNA and RNA analysis for single or molecule detection which includes GOLD for microbiome analysis, monitors to track microbiome modulation, and STRATOS for microbiome profiling.
- Apr 2026Series A$14.1M
- Mar 2023Series A$14M
#2
Series B · Planegg, Bavaria · founded 2009 · 49 employees$26.3Mraised▾
Developer of mRNA therapeutics for infectious diseases. It has two proprietary platforms for SNIM RNA technology (Stabilized Non-Immunogenic mRNA) for transcript therapy and SNIM RNA delivery system. The platforms enable the designing of mRNA for the protein of interest and chemical modification of the nucleotide backbone to bypass the innate immune response and targeted delivery. The pipeline includes therapeutics for COVID-19, respiratory diseases, and Primary ciliary dyskinesia (PCD).
- May 2025Grant (prize money)$11.3M
- Jun 2024Series B$5M
- Feb 2022Series B$26.3M
- Jan 2020Grant (prize money)$550.3K
#3
ATAI 🦄Public · Munich, Bavaria · founded 2018 · 119 employees$386.7Mraised▾
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
#4
Funding Raised · Planegg, Bavaria · founded 2018 · 19 employees$23.1Mraised▾
ISAR Bioscience is the developer of regenerative medicine. The company uses the induced pluripotent stem cell and genome engineering technologies for developing regenerative medicine. It has collaboration with ldc and Assay.Works to develops therapeutic and discovery technology.
- Nov 2023Grant (prize money)$1M
- Grant (prize money)$22.1M
#5
Series F · Munich, Bavaria · founded 1998 · 3 employees$158.1Mraised▾
Isarna Therapeutics develops TGF-B inhibitors that stimulate the human immune system to effectively treat ophthalmic, fibrotic diseases cancer. Its lead product ISTH0036 for ophthalmology is undergoing Phase 1 trials. Other candidates include ISTH1106 for fibrosis, ISTH0047, and ISTH1047 for oncology which are in pre-clinical stage. Its leading candidate ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger ribonucleic acid (mRNA) of TGF-β2. The company received FDA orphan drug designation for ISTH0036, for the prevention of scarring post glaucoma filtration surgery.
- Apr 2014Series F$7.6M
- Jan 2014Series F$17.8M
- Jan 2012Series F$11M
- Jul 2011Series E$11.6M
#6
Acquired · Planegg, Bavaria · founded 1999 · 41 employees$71.3Mraised▾
Discovering drug targets through Deductive Genomics. The company has developed complementary biomedical technologies for both drug discovery and drug target validation. Ingenium has developed several drug discovery approaches based on a unique functional analysis of the mammalian genome at the organism level (Deductive Genomics). Its product includes NGENOtyping a novel, high-speed, genetics tool for in vivo validation of gene-based drug targets by providing the most rapid pathway to genetic mouse and rat models. The company is founded as a spin-off from the German Human Genome Project, is a subsidiary of the integrated drug development company Probiodrug.
- Apr 2006Series D$11.1M
- Apr 2005Grant (prize money)$1.4M
- Dec 2003Series C$16.9M
- Sep 2000Series B$43.3M
#7
Public · Planegg, Bavaria · founded 1997$44.5Mraised▾
GPC Biotech, acquired by Agennix in 2009 was a biopharmaceutical company focussed on oncology. Their pipeline had Satraplatin, a platinum-based small molecule for Hormone-refractory prostate cancer, which was undergoing phase 3 trials and another MAb in Phase I trial relapsed/refractory B-cell lymphoma.
- 2007Grant (prize money)$1.4M
- Feb 2006Post IPO$43.1M
#8
Series C · Planegg, Bavaria · founded 2010 · 29 employees$20.2Mraised▾
Develops instruments, OEM modules and assays for molecular pathogen detection. It claims its technology as a new approach to PCR along with cooling and heating rates at different orders and enables physicians and hospitals to diagnose bacterial diseases. Its first product Pharos400 features laser-based PCR technology is for thermal cycling and fluorescence-free real-time readout of results.
- Aug 2019Series C$13.5M
- Dec 2017Grant (prize money)$2M
- Jun 2015Series B$6.7M
#9
Series B · Tutzing, Bavaria · founded 2008 · 14 employees$1.2Mraised▾
The baseclick technology is based on click chemistry method introduced by Professor Barry Sharpless (Nobel Prize in Chemistry, 2001) of The Scripps Research Institute, La Jolla, California. Professor Thomas Carell of Ludwig-Maximilians-Universität Munich, Germany, has advanced the technology so that nucleic acids can be efficiently modified. The basic patent on copper-catalyzed click reactions on nucleic acids was granted by the European Patent Office in 2010 followed by many other countries such as USA, Japan etc. The company which is spin off of BASF SE and Ludwig-Maximilians-Universität (LMU) hold the IP and licenses it along with providing support for further development.
- Oct 2022Grant (prize money)$255.4K
- Apr 2020Grant (prize money)$539.9K
- Apr 2018Grant (prize money)$306.9K
- Jan 2018Grant (prize money)$300.8K
#10
Seed · Gauting, Bavaria · founded 2023$544.8Kraised▾
Provider of genomic-based test kits for diisease diagnostics. It offers CRISPR-based platform that enables multiplex detection of DNA and RNA biomarkers with the help of Lateral Flow Assays and PCR for multiple disease diagnosis.
- Aug 2023Seed$544.8K
#11
Public · Neuried, Bavaria · founded 2003$3.3Mraised▾
FRIZ Biochem is engaged in the development of in-vitro diagnostic tests , oligonucleotides, and dithiol phosphoramidite. The company has developed DNA-chips based biosensor with direct electrical read-out that allows detection of SNPs (single nucleotide polymorphism), avoiding the need for labeling of the target-DNA. Its product -CYCLE® diagnostics platform is a combination of proprietary sample preparation technology with multiplexed real-time PCR amplification and detection. The cartridge consists of an IC-chip to collect data and all necessary chemicals. The device has a turnaround of 30 minutes.
- Nov 2014Grant (prize money)$62.2K
- Sep 2014Grant (prize money)$65.6K
- Apr 2003Series B$3.3M
#12
Funding Raised · Nuremberg, Bavaria · founded 1997$1.1Mraised▾
MN-AM is a developer of chemoinformatics software for drug discovery. The ChemTunes ToxGPS chemoinformatics software is used for platform and database offers in vitro and in vivo toxicity data for safety evaluation and risk assessment of chemical compounds.
- May 2021Grant (prize money)$1.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Germany
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,605 Germany-affiliated papers.
- Heidelberg University245
- German Cancer Research Center123
- Charité - Universitätsmedizin Berlin95
- Goethe University Frankfurt94
- Ludwig-Maximilians-Universität München91
- Genome13→106
- Gene16→108
- Transcriptome6→61
- Epigenetics2→40
- Context (archaeology)1→33
- Disease1→62
- Gene3→49
- Immune system1→41
- Transcriptome4→37
- Biomarker1→29
- Disease2→41
- Immune system1→29
- Gene4→24
- Genome2→20
- Cancer1→14
Where bioinformatics is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.